Senti Biosciences, Inc. Rochelle Emery Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and ... and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

The partners will use Cellino's autonomous biomanufacturing tech to produce high-quality autologous iPSCs for Karis' ...

(“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell ...

Research and development activities for NK cell therapies are rapidly evolving, backed by significant advancements in immunotherapy-centric cancer treatment approaches. Unlike other immune cells ...

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative ...

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative ...

About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of ...

Among other functions, the NK cells (Natural Killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

NKGen Biotech (NKGN) announced the oral presentation of updated Phase 1 clinical data from the Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy ...